CUSIP 64135M105 · who reports it, how much, and how much it matters to them
17 of the 720 hedge fund managers we track reported shares of Neurogene Inc. (Nasdaq: NGNE) on Form 13F for 30 June 2026. Between them they reported USD 285m. The largest position belongs to Casdin Capital, at USD 49m. The manager with the most riding on it is Redmile Group, where it is 3.0% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Casdin Capital3 funds on PPLI.com | USD 49m | 2.4% |
| 2 | Redmile Group10 funds on PPLI.com | USD 44m | 3.0% |
| 3 | RTW Investments2 funds on PPLI.com | USD 43m | 0.4% |
| 4 | ECOR1 Capital3 funds on PPLI.com | USD 40m | 1.9% |
| 5 | Baker Bros. Advisors2 funds on PPLI.com | USD 31m | 0.2% |
| 6 | Balyasny Asset Management25 funds on PPLI.com | USD 26m | 0.0% |
| 7 | Citadel Advisors32 funds on PPLI.com | USD 13m | 0.0% |
| 8 | Great Point Partners2 funds on PPLI.com | USD 11m | 2.1% |
| 9 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 11m | 0.4% |
| 10 | POINT72 Asset Management17 funds on PPLI.com | USD 4.5m | 0.0% |
| 11 | Moore Capital Management7 funds on PPLI.com | USD 4.5m | 0.1% |
| 12 | Rock Springs Capital Management2 funds on PPLI.com | USD 3.4m | 0.2% |
| 13 | Dafna Capital Management6 funds on PPLI.com | USD 2.8m | 0.5% |
| 14 | Millennium Management6 funds on PPLI.com | USD 1.3m | 0.0% |
| 15 | Renaissance Technologies13 funds on PPLI.com | USD 642,000 | 0.0% |
| 16 | D. E. Shaw & Co.15 funds on PPLI.com | USD 308,000 | 0.0% |
| 17 | Brevan Howard Capital Management39 funds on PPLI.com | USD 264,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Redmile Group | USD 44m | 3.0% |
| 2 | Casdin Capital | USD 49m | 2.4% |
| 3 | Great Point Partners | USD 11m | 2.1% |
| 4 | ECOR1 Capital | USD 40m | 1.9% |
| 5 | Dafna Capital Management | USD 2.8m | 0.5% |
| 6 | Arrowmark Colorado Holdings | USD 11m | 0.4% |
| 7 | RTW Investments | USD 43m | 0.4% |
| 8 | Rock Springs Capital Management | USD 3.4m | 0.2% |
| 9 | Baker Bros. Advisors | USD 31m | 0.2% |
| 10 | Moore Capital Management | USD 4.5m | 0.1% |
Neurogene Inc. trades under the symbol NGNE on the Nasdaq. Its CUSIP, the code used on Form 13F, is 64135M105.
17 of the 720 hedge fund managers PPLI.com tracks reported Neurogene Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Casdin Capital (USD 49m), Redmile Group (USD 44m), RTW Investments (USD 43m), ECOR1 Capital (USD 40m) and Baker Bros. Advisors (USD 31m).
17 managers in our coverage reported it, and between them they run 208 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Redmile Group, where the position was 3.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Neurogene Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.